Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis

Anti-PD-L1 (programmed cell death-ligand 1) agents, such as atezolizumab, have been approved for the treatment of different advanced cancers. However, no study enrolled end-stage renal disease (ESRD) patients, and to our knowledge, there are no significant published data about safety and efficacy of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Case Rep Oncol Med
Main Authors: Parisi, Alessandro, Cortellini, Alessio, Cannita, Katia, Bersanelli, Melissa, Ficorella, Corrado
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi 2019
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6387689/
https://ncbi.nlm.nih.gov/pubmed/30881713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/3452762
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados